Results 121 to 130 of about 159,142 (283)

Beyond Gut Modulation: A Critical Review of the Therapeutic Potential, Safety, and Clinical Prospects of Natural Polysaccharides for IBD

Food Safety and Health, EarlyView.
In this review, we critically summarized the application of natural polysaccharides (NPs) for the treatment of IBD. This approach combines, in a unique way (right), the basic structure–activity relationships of NPs from different origins (left) with their multipronged mode of action, which involves modulation of the gut microbiota and other ...
Felix Danso, A. M. Abd El‐Aty, Kwaku Amoah, Xianghong Ju   +3 more
wiley   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Probiotics‐derived postbiotics improve host metabolic syndrome by activating the adipocyte thermogenic signaling pathway in high‐fat diet‐fed mice

iMetaOmics, EarlyView.
This schematic illustrates how probiotics‐derived postbiotics (PLBK®1–5) combat high‐fat diet‐induced obesity. Postbiotics remodel gut microbiota, boosting beneficial metabolites. These metabolites activate adipocyte thermogenesis (Ucp1/AMPK pathway), resulting in reduced body weight, improved insulin sensitivity, and alleviated hepatic steatosis in ...
Ye Tian, Liujing Huang, Yifan Liu, Xudong Mai, Yanbo Cheng, Bingdong Liu, Yixin Chen, Liwei Xie   +7 more
wiley   +1 more source

Beyond “you are what you eat”: Unlocking gut microbiota‐mediated biotransformation of dietary phytochemicals

iMetaOmics, EarlyView.
The “efficacy paradox” of phytochemicals, low bioavailability yet significant health benefits, is associated with gut microbiota, which biotransforms dietary precursors into bioactive metabolites, enabling systemic effects. Thus, health outcomes of diet depend not just on intake “the rainbow”, but on gut microbial metabolism, redefining “you are what ...
Peng Yang, Ren‐You Gan
wiley   +1 more source

Macrophage extracellular vesicles deliver Mef2d proteins to aggravate Bacteroides fragilis pathogenicity in type 2 diabetes arterial calcification

Interdisciplinary Medicine, EarlyView.
Bacteroides fragilis is associated with type 2 diabetes (T2D) arterial calcification and can be activated by macrophage‐derived extracellular vesicles (EVs). BF takes up EVs via receptor‐mediated endocytosis, and activation is induced by EV‐derived Mef2d, thereby inhibiting ArsR family transcriptional regulator transcription.
Cong Chen, Rong He, Jirong Luo, Zhengfeng Liang, Qunwen Pan, Shuangquan Liu, Jingsong Cao   +6 more
wiley   +1 more source

Empiric Antimicrobial Therapy in Patients with Healthcare-Associated, Hospital-Acquired, or Ventilator-Associated Pneumonia in Septic Shock: Does Antimicrobial Reuse Influence Outcomes? [PDF]

, 2017
Appropriate empiric antimicrobial selection is crucial to the survival of septic shock patients. It is suspected that the use of inadequate empiric therapy occurs commonly in practice.
Stagge, Nicole
core   +1 more source

Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Few approved treatments exist for children with Crohn's disease (CD). The REALITI study retrospectively assessed the effectiveness and safety of ustekinumab in real‐world clinical settings for children with CD. Methods Data were collected from the prospective ImproveCareNow (ICN) registry for pediatric patients (≥ 2 to <18 years old)
Steven J. Steiner, Jeremy Adler, Shehzad A. Saeed, Richard S. Strauss, Kristin M. Howe, Anna Sheahan, Renping Zhang, Kimberly R. Keihn, Katharine Harrow, Kelly K. Olano, David A. Evans, Kim Hung Lo, Nanhua Zhang, Lilianne Kim, Richard B. Colletti, Sheri Volger, for the ImproveCareNow Learning Health Network, Sabina Ali, Rana Ammoury, Keren L. Appel, Travis Ayers, Howard Baron, Julie Bass, Rachel Bensen, Erica J. Brenner, José Cabrera, Mallory Chavannes, J Fernando del Rosario, Jill Dorsey, Dana M. H. Dykes, Dawn R. Ebach, Bhaskar Gurram, Dyer Heintz, Leslie M. Higuchi, Edward J. Hoffenberg, Jeannie S. Huang, Esther Jacobowitz Israel, Traci W. Jester, Ian Kang, Ian Leibowitz, Tiffany Linville, Ross M. Maltz, Craig A. McKinney, Lybil B. Mendoza Alvarez, Phillip Minar, Tina Morhardt, Alisa J Muñiz Crim, Barbara Joanna Niklinska‐Schirtz, Daniel M. O'Connell, Helen Pappa, Brad Pasternak, Trusha Patel, Meryl K. Perlman, Kelly C. Sandberg, Marc E. Schaefer, Robbyn E. Sockolow, David L. Suskind, Gitit Tomer, Jeanne Tung, Amanda A. Wenzel, Denise D. Young   +60 more
wiley   +1 more source

Point of care tests for hospital-acquired infections (HAIs) : economic analysis report [PDF]

A number of clinical/disease areas have been prioritised by the Technology Strategy Board (TSB) and Department of Health (DH) for the DIIA Innovation Platform.
Osipenko, Leeza, Szczepura, Ala
core  

Eubiosis and dysbiosis: the two sides of the microbiota [PDF]

, 2016
The microbial ecosystem of the gastrointestinal tract is characterized by a great number of microbial species living in balance by adopting mutualistic strategies. The eubiosis/dysbiosis condition of the gut microbiota strongly influences our healthy and
Cacciotti, Fatima, Cicerone, Clelia, Corazziari, Enrico Stefano, Gagliardi, Antonella, Iebba, Valerio, Mancini, Carlo, Pantanella, Fabrizio, Santangelo, Floriana, Schippa, Serena, Totino, Valentina, Trancassini, Maria   +10 more
core  

Gastrointestinal manifestations following chimeric antigen receptor T‐cell (CAR‐T) 19 therapy in pediatric patients with CD19+ acute lymphoblastic leukemia

JPGN Reports, EarlyView.
Abstract Pediatric patients with CD19+ acute lymphoblastic leukemia (ALL) undergoing chimeric antigen receptor T‐cell (CAR‐T) therapy frequently experience gastrointestinal (GI) complications. A retrospective study analyzed 13 patients (median age: 8 years) treated between January 2020 and January 2024.
Judith Raya Muñoz, Melissa Panesso Romero, Saray Mesonero Cavia, Marta Freixas Bermejo, Vanessa Cabello Ruiz, Marina Álvarez Beltran, Maria Cristina Díaz de Heredia Rubio, Susana Elena Redecillas Ferreiro, Oscar Segarra Canton   +8 more
wiley   +1 more source